Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

54.31
Delayed Data
As of Jun 24
 -2.64 / -4.64%
Today’s Change
49.96
Today|||52-Week Range
137.89
-42.31%
Year-to-Date
3 Biotech Stocks to Buy in July
3:22pm / MotleyFool.com - Paid Partner Content
'Mad Money' Lightning Round: Buy, Buy, Buy UnitedHealth Group
9:03am / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close56.95
Today’s open54.00
Day’s range53.00 - 55.54
Volume1,812,647
Average volume (3 months)993,890
Market cap$4.6B
Dividend yield--
Data as of 4:00pm ET, 06/24/2016

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-43.49%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book3.65

Competitors

 Today’s
change
Today’s
% change
CRLCharles River Labora...-3.83-4.55%
ICLRICON PLC+0.21+0.31%
PRXLPAREXEL Internationa...-1.20-1.98%
IONSIonis Pharmaceutical...-1.63-6.91%
Data as of 4:02pm ET, 06/24/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$1.25
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President &
Chief Operating Officer
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs